1. Scrip
  2. >>Business

Bayer, Curadev Enter ‘STING’ Pact Exploring Inflammatory Disease

Duo Using Curadev’s Stimulator Of Interferon Genes Antagonist Platform

 
• By Sten Stovall

Bayer and Curadev entered a research collaboration and license agreement to develop novel STING antagonists targeting inflammatory disease.

Inflammation_Stethoscope
The STING agonist program aims to kick-start innate immune responses in tumors • Source: Shutterstock

German drug maker Bayer AG has entered a research and licensing agreement with privately held Curadev Pharma Pvt. Ltd. of India to explore and develop so-called stimulation of interferon genes (STING) antagonists across a number of inflammatory diseases, beginning initially in lung and heart conditions.

Curadev is a small molecule drug discovery biotech whose small molecule STING antagonist program aims to discover and develop inhibitors of the intracellular stimulator of interferon genes (STING) pathway, which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.